The reversible TKIs erlotinib and gefitinib, which selectively target EGFR, were shown to improve disease outcomes in non-small-cell lung cancer (NSCLC) patients with EGFR mutations, and this ...

Reports looking at Erlotinib for the treatment of non-small cell lung cancer and the risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel. Erlotinib ...